 |
AcompliaReport |
|
|
 |
Your INDEPENDENT source of news about the diet drug Acomplia (rimonabant) | |||||||||||
|
|||||||||||||
| Acomplia News from December 2006 -- News about Rimonabant | |
Sanofi: FDA Action on Diet Drug Acomplia Not Expected Until April 26th |
|
Sanofi-Aventis grudgingly conceded on Dec. 8th that the U.S. Food and Drug Administration has placed highly anticipated diet drug rimonabant (Acomplia / Zimulti) on a slow track for review, and said it now hopes for an FDA decision on approval of the diet pill by April 26th.
|
|
We subscribe to the HONcode principles of the HON Foundation. This is an independent news site reporting on rimonabant, a diet drug developed by Sanofi-Synthelabo Inc., which plans to market it under the trademarked name Acomplia. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.
(c) 2004-2006 Medical Week News, Inc. All Rights Reserved
Last Updated: 12/08/2006